Labeling crossover

Darwish M, Kirby M, Robertson P, Tracewell W, and Jiang JG (2006) Pharmacokinetic properties of fentanyl effervescent buccal tablets A phase I, open-label, crossover study of single dose 100, 200, 400, and 800 micrograms in healthy adult volunteers. Clin. Ther. 28 707-714. 

Calara F, Taylor K, Han J, Zabala E, Carr EM, Wintle M, Fineman M. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005 27 210-5. 

Portoles, A., Terleira, A., Almeida, S., et al. Bioequivalence study of two formulations of enalapril, at a single oral dose of 20 mg (tablets) A randomized, two-way, open-label, crossover study in healthy volunteers. Curr. Ther Res. 65(1) 34—46, 2004. 

Aldol reactions of both (E)- and (Z)-ketene acetals are highly susceptible to KOBuc catalysis. In the presence of 5 mol% of KOBuc, aldol reactions proceeded to completion within minutes at -78 °C < 1994JA7026>. A double-label crossover experiment, devised to probe the nature of the silicon group transfer in the alkoxide-catalyzed aldol reaction, suggested that free metal enolates are the true reactive species adding to the aldehydes. 

This was a single-center, randomized, four-way, open-label, crossover comparison of three different doses of Orahn on three study days (five, ten and 20 puffs), and on one occasion subcutaneous injection of 0.1 unitkg in 11 male or female subjects with type 1 diabetes. The inclusion criteria included a FBG of 72-180 mg dL during the screening process, an absence of other clinical anomahes except from those derived from their metabohc condition that were relatively minor a physical examination without reasonably major clinical abnormalities a normal EKG HbAlc <11% (normal range 4.5-6.2%) and body mass index (BMI) <28 kg... 

The oxidation of Cp IrH(CH3)(PMej) in MeCN requires two equivalents of ferrocenium and leads to the formation of [Cp Ir(PMe3)(MeCN)2] and CH4. The reductive elimination is intramolecular, as shown by a labelling crossover... 

Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004 26(12) 2034-2044. 

Kapil R, Nolting A, Rov P, Fiske W, Benedek I, Abramowitz W. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen two randomized, open-label, crossover studies in healthy adult volunteers, Clin Ther (2004) 26, 2015-25. 

In an open-label, crossover study in 18 healthy subjects, administration of heparin on day 5 of treatment with 40 mg of intravenous parecoxib twice daily for 6 days produced no clinically or statistically significant differences in coagulation parameters (PT, aPTT and platelet counts), when compared with heparin alone (bolus dose of heparin 4000 units then a 36-hour infusion of 10 to 14 units/kg). Use of these drugs together was well tolerated. However, prolongation of bleeding time was not assessed. ... 

An open label crossover trial in 14 healthy subjects found that cimetidine 400 mg twice daily had no effect on the pharmacokinetics of repaglinide 2 mg three times daily4 ... 

In an open-label crossover study, 24 healthy subjeets were given roxati-dine 150 mg with 10 mL of Maalca (aluminium/magnesium hydroxide) four times daily. The pharmaeokineties of roxatidine were unehanged, apart from a clinically insignificant lengthening of the half-life. ... 

An open-label crossover study in 22 healthy subjects found that the pharmacokinetics of lovastatin 20 mg given with a meal were not significantly affected when colesevelam 2.25 g was given at the same time. ... 

A randomised, open-label, crossover study in 24 healthy subjects found no evidence of any signiflcant pharmacokinetic interaction between a single 300-mg dose of bupropion (sustained release preparation) and a single 800-mg dose of cimetidine. No special precautions would seem to be necessary on concurrent use. 

Musson DG, et al. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food a randomized, open-label, crossover study in healthy adults. Qin Ther. 2010 32(2) 338 6. 

Darwish M, Xie F. Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly a randomized, open-label, crossover study. Drugs Aging 2009 26(2) 95-101. 

Oxidative addition of Mel is followed by reductive elimination. The possibility of binuclear reductive elimination is suggested from the label crossover data. 

Krishna G, Moton A, Ma L, Savant I, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam a phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009 31(2) 286-98. 

Tylicki L, Rutkowski P, Renke M, Larczyski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Triple pharmacological blockade of the renin-angio-tensin-aldosterone system in nondiabetic CKD an open-label crossover randomized controlled trial. Am J Kidney Dis 2009 52 486-93. 

It was unambiguously established that these reactions proceed by direct silicon group transfer by the double-label, crossover experiment (eq 11). The ketene acetal 4 reacted extremely rapidly... 

---